Watching Morphic; Traders Circulate 'MP009 Clinical Proof Of Principle And Favorable Tolerability Profile Shown With Orally Dosed MORF-057 As Induction Therapy For Moderately To Severely Active UC: Phase 2a Emerald-1 Study Results'; Shares Trading Lower

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!